According to the Global Generic Sterile Injectables Market, by Drug Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulins, Blood Factors, Antibiotics, and Others), by Therapeutic Application (Cancer, Metabolic Diseases, Cardiovascular Diseases, Central Nervous System Disease, Infectious Disorders, Musculoskeletal Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 38,706.5 million in 2022 and is expected to exhibit a CAGR of 10.3% during the forecast period (2022-2030).

Market players entered into agreement with other manufacturers, in order to expand their product portfolio. This is expected to drive growth of the global generic sterile injectables market over the forecast period. For instance, in April 2019, Caplin Point Laboratories, a pharmaceutical company, entered into a license and supply agreement with Baxter Healthcare Corporation for five generic injectable portfolio. Under this agreement, Caplin Point Laboratories, licensed out five of its injectable Abbreviated New Drug Applications (ANDAs) to Baxter Healthcare Corporation and the Caplin Point Laboratories entered into license and supply agreement with the Baxter Healthcare Corporation.

Key players are indulged in receiving approvals for their generic injectables from the regulatory authorities, in order to increase the market share in the global market. For instance, in January, 2018, Baxter International Inc. announced the U.S. FDA approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin). It is a direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention. Furthermore, Bivalirudin was launched in the U.S. in early 2018, in two commonly prescribed dosage forms and strengths: 250 mg of bivalirudin per 50 mL (5 mg/mL) and 500 mg of bivalirudin per 100 mL (5 mg/mL).

Global Generic Sterile Injectables Market- Impact of Coronavirus (COVID – 19) Pandemic

The coronavirus disease (COVID-19) pandemic is expected to restrain growth of the global generic sterile injectables market over the forecast period. COVID-19 is the recent pandemic outbreak, which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on May 15, 2020. According to the World Health Organization (WHO) Weekly epidemiological update on COVID-19, the number of new cases as of May 15, 2022 are approximately 518 million confirmed cases and over six million deaths have been reported globally.

Market players are entering into agreements with other market players, in order to supply generic sterile injection for the treatment of COVID-19. This is expected to drive the growth of the global generic sterile injectable market, over the forecast period. For instance, in 2021, Endo International plc, Par Sterile Products business supplied VASOSTRICT, vasopressin injection, USP, vial presentations to healthcare providers through Premier's Premier ProRx program, helping to maintain supply continuity for a medication needed in critical care, including some of the most acute cases of COVID-19.

 Browse 52 Market Data Tables and 47 Figures spread through 387 Pages and in-depth TOC on Global Generic Sterile Injectables Market, by Drug Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulins, Blood Factors, Antibiotics, and Others), by Therapeutic Application (Cancer, Metabolic Diseases, Cardiovascular Diseases, Central Nervous System Disease, Infectious Disorders, Musculoskeletal Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the generic sterile injectables market, click the link below:

https://www.coherentmarketinsights.com/market-insight/generic-sterile-injectable-market-519

Market players are focusing on signing agreements with other market players for the expansion of new manufacturing facility. This is expected to increase the growth of the global generic sterile injectables market, over the forecast period. For instance, in May 2017, Russian pharmaceutical company, NovaMedica began building a pharmaceutical manufacturing plant for sterile injectable drugs at the Vorsino Industrial Park, Kaluga, Russia. In March 2018, NovaMedica signed a special investment contract (SPIC) with the Ministry of Industry and Trade of the Russian Federation and the Kaluga Region. The investor will be responsible for developing the project, while the government will provide stable regulations and incentives.

Key Takeaways of the Generic Sterile Injectables Market:

  • The global generic sterile injectables market is expected to exhibit a CAGR of 10.3% over the forecast period (2022-2030), owing to growth in potential markets, especially in Europe. While North America accounted for the major market share.
  • Market players are indulged in receiving approvals from the regulatory authorities and this is expected to drive the growth of the global generic sterile injectables market, over the forecast period. For instance, in June 2019, Merck & Co., Inc. received the U.S. Food and Drug Administration (FDA) approval for its anti-PD-1 therapy, KEYTRUDA as monotherapy in patients whose tumor express PD-L1 or in combination with platinum and fluorouracil (FU) for the first-line treatment of patients with recurrent head and neck squamous cell carcinoma (HNSCC).
  • Some of the major players operating in the global generic sterile injectables market include Baxter International Inc., AstraZeneca plc, Merck & Co., Inc., Pfizer Inc., Fresenius Kabi, Novartis International AG, Teva Pharmaceuticals, Hikma Pharmaceuticals, Dr. Reddy’s Laboratory, Mylan N.V., and Sun Pharmaceutical Industries Ltd.

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo